Holland & Knight Health Dose: June 4, 2024

HK
Holland & Knight

Contributor

Holland & Knight is a global law firm with nearly 2,000 lawyers in offices throughout the world. Our attorneys provide representation in litigation, business, real estate, healthcare and governmental law. Interdisciplinary practice groups and industry-based teams provide clients with access to attorneys throughout the firm, regardless of location.
Holland & Knight Health Dose is an in-depth weekly dose of legislative and regulatory insights to keep stakeholders abreast of happenings in Washington, D.C., impacting the health sector.
United States Food, Drugs, Healthcare, Life Sciences
To print this article, all you need is to be registered or login on Mondaq.com.

Holland & Knight Health Dose is an in-depth weekly dose of legislative and regulatory insights to keep stakeholders abreast of happenings in Washington, D.C., impacting the health sector.

This week's topics include:

  • Senate Finance Committee Members Drafting Bipartisan GME Bill
  • Legislation to Prohibit Biotechnology Contracting with Foreign Adversaries
  • Sen. Paul Files Resolution on Laboratory Developed Tests
  • Congress Members Request Expanded Digital Therapeutics Coverage
  • Bipartisan Group of Legislators on E&C Health Subcommittee Introduce 340B Legislation
  • At Rep. Pallone's Request, GAO Releases Prior Authorization Report
  • Senate HELP Committee Approves Six Measures
  • House Hearings on Healthcare Consolidation
  • New Preventive Health Caucus
  • Congressional Retirements and Resignations
  • FDA: AI Guidance to Address Data Quality, Transparency, Standard Definitions
  • NIH Releases Equitable and Affordable Access Proposal and RFI
  • OCR Guidance Reversal
  • CMS Oncology Model Expansion

Read the full Health Dose »

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More